• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » MassDevice podcast: BG Medicine CEO Dr. Pieter Muntendam

MassDevice podcast: BG Medicine CEO Dr. Pieter Muntendam

March 24, 2011 By Brad Perriello

When BG Medicine (NSDQ:BGMD) took itself public last month, three years after first announcing (then scuttling) its first initial public offering, investors seemed to like what they saw. Sure, the company cut its share price in half just ahead of the $7-per-share offering Feb. 11, but shares have averaged nearly $8.41 since then — a 20.1 percent increase.*

Investors must like what they know of Waltham, Mass.-based BG and its galectin-3 diagnostic test for heart failure. The test detects the galectin-3 protein, which president and CEO Dr. Pieter Muntendam says is both a biomarker and the cause of a form of heart failure in which the heart muscle gradually stiffens.

Read more of MassDevice.com’s coverage of BG Medicine

But when we sat down with Muntendam earlier in March, he told us that the company’s greatest innovation may not be its first diagnostic but its business model, which turns the traditional path for getting a test to market on its head.

BG Medicine CEO Dr. Pieter Muntendam

Muntendam

Instead of just running the clinical studies needed to validate the galectin-3 test and handing it off to one of the industry’s larger players to take it to market, BG took the test from the clinical stage, through 510(k) clearance from the FDA and CE Mark approval in the European Union, and on to the market. Muntendam said the key challenge was convincing the larger players — BG has deals with Abbott (NYSE:ABT), Siemens (NYSE:SI), Alere (NYSE:ALR) and BioMérieux (EPA:BIM) — that the model would work. They’d have to buy into the idea that developing a test for their high-throughput devices would be a money-maker.

"Probably the most significant re-engineering we did was the re-engineering of the business model. The old business model was, an academic center finds something, they go to an Abbott or a Siemens or whatever, and do an exclusive deal. So [the inventors] don’t develop it," he explained. "We said, ‘No, no, no, we’re turning this into a full product.’ Now I’ve paved the way for automated versions to follow."

Galectin-3 test

Galectin-3 test

Galectin-3 is just the beginning, Muntendam added. The company is working on a project to develop a test for the type "vulnerable plaque" he said is implicated in deadly first-time heart attacks, again with the help of deep-pocketed corporate partners — Astra Zeneca (NYSE:AZN), Takeda Pharmaceutical (PINK:TKPYY), Merck (NYSE:MRK), Philips (NYSE:PHG) and GE (NYSE:GE) — and with the Framingham Heart Study. He’s also got his sights set on multiple sclerosis, he said.

"The key thing for us is to finish galectin-3 and get it out there. We’ll do the same, I predict, for heart attacks, and do the next one," Muntendam said. "We can do this many, many times over. There are so many unmet needs left."

Click here to listen to the podcast for free. You can also download an MP3 of the interview by right-clicking.

*Correction, March 24, 2011: This article originally and erroneously stated that BG Medicine’s IPO débuted at $8.00 per share. Return to the corrected sentence.

Filed Under: Device Talks Podcasts, Diagnostics, News Well Tagged With: BG Medicine Inc., Cardiac Markers, MassDevice Q&A

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy